Literature DB >> 3932059

[Interferon in chronic polyarthritis. Positive effect in clinical evaluation].

H J Obert, P H Hofschneider.   

Abstract

During the last two years, 80 patients with definite chronic rheumatoid arthritis were treated with interferon-gamma. Considerable improvement in the clinical picture occurred in 58, with pain decreasing rapidly and lastingly or even disappearing. Even in largely immobile patients the ability to walk and general mobility were nearly fully restored. The treatment was well tolerated in 74 patients. As the substance is administered subcutaneously it is suitable for out-patient treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932059     DOI: 10.1055/s-2008-1069083

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  13 in total

Review 1.  Ten years research on inflammation revisited.

Authors:  K Brune
Journal:  Agents Actions       Date:  1989-01

2.  Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma.

Authors:  E M Lemmel; M Franke; W Gaus; P W Hartl; P H Hofschneider; K Miehlke; K Machalke; H J Obert
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

3.  The effect of treatment with interferon-gamma on type II collagen-induced arthritis.

Authors:  H Nakajima; H Takamori; Y Hiyama; W Tsukada
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

4.  Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma.

Authors:  E M Lemmel; D Brackertz; M Franke; W Gaus; P W Hartl; K Machalke; H Mielke; H J Obert; H H Peter; J Sieper
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

5.  The influence of interferon-gamma, interleukin-2, prostaglandin E2, and cyclosporine on the polyclonal and anti-DNA antibody secretion in lymphocyte cultures derived from patients with systemic lupus erythematosus.

Authors:  H D Volk; N Sönnichsen; S Jahn; F Hiepe; E Apostoloff; R von Baehr; W Diezel
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

6.  Spontaneous and in vitro activation of synovial fluid and peripheral blood lymphocytes in rheumatoid arthritis.

Authors:  Y T Konttinen; T Pettersson; P Kemppinen; C Friman
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

Review 7.  [Interferon therapy and autoimmunity].

Authors:  J Fritzsch; J Krug; H J Heberling
Journal:  Med Klin (Munich)       Date:  1997-05-15

Review 8.  Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines.

Authors:  Eugene Y Kim; Kamal D Moudgil
Journal:  Cytokine       Date:  2017-04-25       Impact factor: 3.861

9.  Depressed PPD and tetanus toxoid presentation by monocytes to T lymphocytes in patients with rheumatoid arthritis: restoration by interferon gamma.

Authors:  M Seitz; I Napierski; H Kirchner
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

10.  Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

Authors:  S J Hopkins; A Meager
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.